# Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

> **NCT00071396** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Campath-1H
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00071396
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-09
- **Final completion:** 2007-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071396, "Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00071396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*